The Motley Fool

Volpara share price charges higher after completing MRS Systems acquisition

The Volpara Health Technologies Ltd (ASX: VHT) share price is on course to finish the week with a strong gain.

On Friday afternoon the medical technology company’s shares are up almost 5.5% to $1.69.

Why is the Volpara share price charging higher?

Investors appear to have been scrambling to pick up the company’s shares today after it announced the completion of its US$14.59 million (~A$21.15 million) acquisition of MRS Systems.

MRS Systems is a medical software company that provides comprehensive patient tracking and communication, and a radiology reporting platform for sub-specialty radiology applications including breast and lung imaging.

It is a leading provider of breast clinic management software, with an estimated ~20% market share of breast clinics in the United States.

In the 2019 calendar year the company has forecast annual recurring revenue (ARR) of ~US$4.5 million. Including capital sales, MRS Systems expects ~US$7.5 million of total revenue over the 12 months.

Volpara made the acquisition as it provides it with an expanded and mature presence in the United States, an enlarged sales footprint and technical support, and product suites that are highly complementary. The latter is expected to provide both businesses with cross-selling opportunities.

In addition to this, management believes the combination of MRS clinical data and Volpara images will enrich Volpara’s AI capability.

Volpara’s CEO, Dr Ralph Highnam, said: “We are delighted to welcome MRS Systems and its people into the Volpara group. And we are excited about the opportunity to work alongside MRS Systems in the United States and to grow Volpara’s service offering in the increased number of US breast clinics to which Volpara now has immediate access. The acquisition has involved a tremendous effort from people in both organisations, and I would like to express my thanks to everyone as we look forward to the future with a stronger US base and an extended range of integrated products which will help detect breast cancer earlier.”

Volpara isn’t the only medical technology company on the rise today. The shares of both Nanosonics Ltd (ASX: NAN) and Pro Medicus Limited (ASX: PME) are outperforming the market by some distance on Friday.

And here is another small cap healthcare share that could be just as exciting as Volpara.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of VOLPARA FPO NZ. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited and Pro Medicus Ltd. The Motley Fool Australia has recommended VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.